Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient

Pharmacotherapy

Volumn 26, Issue 2, 2006, Pages 289-295

  Said, Ahmed ^a   Garnick, James J ^c   Dieterle, Natalie ^d   Peres, Edward ^b,d   Abidi, Muneer H ^b,d   Ibrahim, Rami B ^a,c,d  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Cytochrome P450 3A4; Drug interactions; Inhibition; Itraconazole; Metabolism; P glycoprotein; Sirolimus

Indexed keywords

ALEMTUZUMAB; ANTIFUNGAL AGENT; BUSULFAN; CALCINEURIN INHIBITOR; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; LEVOFLOXACIN; METHOTREXATE; MORPHINE; MYCOPHENOLIC ACID; OXYBUTYNIN; PANTOPRAZOLE; PENICILLIN DERIVATIVE; PENTAMIDINE; PROBENECID; PYRROLE DERIVATIVE; RANITIDINE; RAPAMYCIN; TACROLIMUS; VALGANCICLOVIR; VORICONAZOLE;

ADULT; AFRICAN AMERICAN; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENCY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LIVER DYSFUNCTION; MALE; MULTIPLE ORGAN FAILURE; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; ORGAN TRANSPLANTATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TOXICITY; URINARY TRACT INFECTION; VIRUS INFECTION;

ADENOVIRIDAE INFECTIONS; ADULT; ANEMIA, APLASTIC; ANTIFUNGAL AGENTS; BONE MARROW TRANSPLANTATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FATAL OUTCOME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ITRACONAZOLE; MALE; MYELODYSPLASTIC SYNDROMES; SIROLIMUS;

EID: 32044468744     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.2.289     Document Type: Article

References (32)

1. Vasquez E. Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health-Syst Pharm 2000;57:437-51.
2. Ingle GR, Sievers TM, Holt CD. Sirolimus: continuing the evolution of transplant immunosuppression. Ann Pharmacother 2000;34:1044-55.
3. Cutler CA, Antin JH. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004;34(6):471-6.
4. Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Safety 1997;16(4):267-78.
5. Grigg AP, Brown M, Roberts AW, Szer J, Slavin MA. A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation. Bone Marrow Transplant 2004;34(5):447-53.
6. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103(4):1527-33.
7. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003;138(9):705-13.
8. Cervelli MJ, Russ GR. Itraconazole-tacrolimus drug interaction. Ther Drug Monit 2003;25(4):483-4.
9. Kramer MR, Merin G, Rudis E, et al. Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506). Transplant Proc 1997;29(6):2657-9.
10. Potter M, Donnelly JP. The role of itraconazole in preventing and treating systemic fungal infections in immunocompromised patients. Acta Haematol 2003;111:175-80.
11. Marr KA, Leisenring W, Grippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004;103(4):1557-9.
12. Pfizer Inc. Vfend (voriconazole) package insert. New York, NY; 2003.
13. Kuypers DR, Claes K, Evenepoel P, et al. Drug interaction between itraconazole and sirolimus in a primary renal allograft recipient [letter]. Transplantation 2005;79(6):737.
14. Sadaba B, Campanero MA, Quetglas EG, Azanza JR. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc 2004;36:3226-8.
15. Janssen Pharmaceuticals. Sporanox (itraconazole) product information. Beerse, Belgium; 2003.
16. Wyeth-Ayerst Laboratories. Rapamune (sirolimus) package insert. Philadelphia, PA; 2004.
17. Garland A, Paz HL. Outcome of marrow transplantation recipients requiring intensive care. Semin Respir Crit Care Med 1996;17:359-63.
18. Benito AI, Furlong T, Martin PJ, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute GVHD. Transplantation 2001;72:1924-9.
19. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001;40(8):573-85.
20. Floren L, Christians U, Zimmerman JJ, et al. Sirolimus oral bioavailability increases ten-fold with concomitant ketoconazole [abstr]. Clin Pharmacol Ther 1999;65(2):159.
21. Thomas PP, Manivannan J, John GT, et al. Sirolimus and ketoconazole co-prescription in renal transplant recipients. Transplantation 2004;77(3):474-5.
22. Cervelli M. Fluconazole-sirolimus drug interaction. Transplantation 2002;74(10):1477-8.
23. Isoherranen N, Kunze KL, Allen KE, et al. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Disp 2004;32:1121-31.
24. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004;43(2):83-95.
25. Kovarik J, Hsu C, McMahon L, et al. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001;70(3):247-54.
26. Morris R. Immunosuppressant drug monitoring: is the laboratory meeting clinical expectations? Ann Pharmacother 2005;39(1):119-27.
27. Antin JH, Kim HT, Cutler C, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003;102:1601-5.
28. Cutler C, Kim HT, Hochberg E, et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004;10:328-36.
29. Johnston LJ, Brown J, Shizuru JA, et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:47-55.
30. Couriel DR, Hicks K, Saliba R, et al. Sirolimus (rapamycin) for treatment of steroid-refractory chronic graft versus host disease [abstr]. Biol Blood Marrow Transplant 2003;9:67a.
31. Naranjo C, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
32. Ibrahim RB, Abella EM, Chandrasekar PH. Tacrolimus-clarithromycin interaction in a patient receiving bone marrow transplantation [letter]. Ann Pharmacother 2002;36(12):1971-2.